ANDA 60770, held by Hikma Pharmaceuticals. Oxytetracycline Hydrochloride.
As of Nov 21, 2026, ANDA 60770 (Oxytetracycline Hydrochloride), held by Hikma Pharmaceuticals, was first approved by FDA on Sep 29, 1967, with 3 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 29, 1967 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Oxytetracycline HydrochlorideEQ 250MG BASE · capsule;oral | Oxytetracycline Hydrochloride | Discontinued |
| Mar 31, 2025 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jun 11, 1991 | Supplement 3Manufacturing | Approved | None posted |
| Dec 10, 1990 | Supplement 2Labeling | Approved | None posted |
| Sep 29, 1967 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters